Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Incyte Corp (NQ: INCY )

70.94 -0.20 (-0.29%)
Streaming Delayed Price Updated: 2:18 PM EDT, Mar 30, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Incyte Corp

< Previous 1 2 3 4 5 6 7 Next >
What 13 Analyst Ratings Have To Say About Incyte
 
Via Benzinga
Second Setback For Incyte's LIMBER Program - Analyst Says 'Resolution Timelines Unclear To Assess Impact'
 
Via Benzinga
Incyte Stock Dives On Surprise Rejection For Updated Jakafi
The company had hoped to gain approval for an extended-release version of its biggest drug. 
Via Investor's Business Daily
Incyte Would Now Compete With Merck, Pfizer As Its Skin Cancer Treatment Scores FDA Accelerated Approval
 
Via Benzinga
7 Healthcare Stocks to Buy for Long-Term Growth and Stability
These healthcare stocks to buy offer spectacular upside potential ahead in your defensive portfolio as we get deeper into 2023. 
Via InvestorPlace
Why Shares of MacroGenics Climbed Thursday
The cancer-focused biotech delivered a strong earnings report. 
Via The Motley Fool
Analyst Expectations for Incyte's Future
 
Via Benzinga
Incyte's Return On Capital Employed Overview
 
Via Benzinga
Analyst Ratings for Incyte
 
Via Benzinga
Earnings Outlook For Incyte
 
Via Benzinga
Which S&P 500 Stocks Look Most Attractive Now?
Using ValuEngine’s advanced screening tool, we select 4- and 5-rated stocks in the SPY ETF. As we can see in the table below, 20 stocks passed the screen with two strong buys; CEG and NCLH. 
Via Talk Markets
Incyte Discontinues LIMBER-304 On Doubts Regarding Meeting Primary Goal, Analyst Says It Underpins Some Investor Concerns
 
Via Benzinga
Incyte, Haemonetics Post Earnings Beats; One Surges Within Buy Zone
Haemonetics stock rose within a buy zone on Tuesday, but Incyte stock toppled. 
Via Investor's Business Daily
Incyte Q4 Earnings Beat Street View, But Guidance Is Conservative Says Analyst
 
Via Benzinga
2 Steady Stocks to Buy in a Recession
Both companies are performing better than the broader market over the past year. 
Via The Motley Fool
Benzinga's Top Ratings Upgrades, Downgrades For January 31, 2023
 
Via Benzinga
Golden Cross Appears Before Incyte Investors
 
Via Benzinga
Expert Ratings for Incyte
Incyte (NASDAQ:INCY) has observed the following analyst ratings within the last quarter: 
Via Benzinga
Incyte Stock Clears Technical Benchmark, Hitting 80-Plus RS Rating
On Thursday, Incyte stock hit a key performance benchmark, with its Relative Strength (RS) Rating jumping to 82, up from 78 the day before. 
Via Investor's Business Daily
7 Biotech Stocks That Will Make You Rich in 10 Years
Although the health innovation space is risky, the opportunities beckon a look at the biotech stocks that will make you rich in 10 years. 
Via InvestorPlace
BriaCell Therapeutics' Mission: Destroy Breast & Prostate Cancers
From my analysis of BriaCell, it would make a great buy and hold investment. If, and when, it is bought out by a major pharmaceutical company, or brings a product directly to market itself, its stock... 
Via Talk Markets
Why These 7 Healthcare Stocks Could Soar in 2023
These healthcare stocks to buy are trading at a hefty discount and are poised to deliver robust returns in 2023. 
Via InvestorPlace
Week In Review: Ten Biggest 2022 China Biopharma Deals Worth $21.5 Billion
China Biopharma deal activity in 2022 was certainly slower than the previous year, but the ten largest deals, many of them booked in the second half of the year, totaled a decent $21.5 billion by... 
Via Talk Markets
2 Cathie Wood Stocks to Buy and Hold Through 2023 and Beyond
These two biotechs are flying high right now. 
Via The Motley Fool
The 7 Hottest Healthcare Stocks to Own for 2023 and Beyond
These seven hottest healthcare stocks have strong growth catalysts that could send each of them higher over the next few years. 
Via InvestorPlace
Cramer Says He's 'Always Liked' This Drug Company
On CNBC’s "Mad Money Lightning Round," Jim Cramer said Oshkosh Corporation (NYSE: OSK) is a "slow grower. 
Via Benzinga
BriaCell's Positive Clinical And Quality Of Life Data In Advanced Metastatic Breast Cancer Could Provide Hope For Patients
Small and big pharma companies such as Pfizer Inc. (NYSE: PFE), Celldex Therapeutics Inc. (NASDAQ: CLDX), and Hologic Inc. (NASDAQ: HOLX< 
Via Benzinga
7 Cash-Rich Stocks to Buy for Peace of Mind
It pays to hold cash-rich stocks that can weather any storm because of their financial strength. Investors may want to watch these seven. 
Via InvestorPlace
2 Biotech Stocks That Could Make You Richer
Both drugmakers are pretty close to their 52-week highs, but that shouldn't stop investors. 
Via The Motley Fool
Recap: Incyte Q3 Earnings
Incyte (NASDAQ:INCY) reported its Q3 earnings results on Tuesday, November 1, 2022 at 07:00 AM. Here's what investors need to know about the announcement. Earnings Incyte missed estimated earnings by... 
Via Benzinga
< Previous 1 2 3 4 5 6 7 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.